| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 145 | 7.627 | 14.651 | 144.469 | 113.118 | 32.729 | 95.965 | 49.418 |
| Total Income - EUR | - | - | 145 | 7.627 | 14.651 | 146.903 | 113.325 | 33.760 | 95.975 | 49.433 |
| Total Expenses - EUR | - | - | 337 | 6.968 | 8.904 | 103.858 | 100.476 | 40.127 | 75.122 | 52.605 |
| Gross Profit/Loss - EUR | - | - | -192 | 660 | 5.747 | 43.045 | 12.849 | -6.367 | 20.853 | -3.172 |
| Net Profit/Loss - EUR | - | - | -196 | 507 | 5.307 | 41.820 | 11.854 | -6.654 | 19.911 | -4.430 |
| Employees | - | - | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Nergismed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 84 | 97 | 719 | 611 | 108 | 34 | 1.069 | 392 |
| Current Assets | - | - | 96 | 4.619 | 16.090 | 70.382 | 70.737 | 54.483 | 28.528 | 24.483 |
| Inventories | - | - | 0 | 768 | 1.960 | 22.047 | 28.066 | 21.074 | 18.218 | 13.837 |
| Receivables | - | - | 0 | 3.634 | 13.354 | 17.166 | 6.516 | 3.873 | 3.090 | 6.372 |
| Cash | - | - | 96 | 216 | 775 | 31.169 | 36.155 | 29.537 | 7.220 | 4.275 |
| Shareholders Funds | - | - | -152 | 357 | 5.657 | 47.370 | 56.216 | 45.468 | 19.960 | 9.756 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 333 | 4.365 | 11.188 | 23.813 | 14.777 | 9.262 | 9.768 | 15.205 |
| Income in Advance | - | - | 0 | 0 | 0 | 44 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4791 - 4791" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Nergismed S.r.l.